Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thrombophilia, hypofibrinolysis and osteonecrosis.

Orthopadie (Heidelberg, Germany)·2025

Same author

Turner's Syndrome, Glucagon-like Peptide 1, and Glucose-dependent Insulinotropic Polypeptide Agents: Silver Bullets?

The Journal of clinical endocrinology and metabolism·2024

Same author

Familial Thrombophilia Is Associated With Primary Multifocal Osteonecrosis: A Case-Control Study of 40 Patients.

Orthopedics·2023

Same author

A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancer.

Laryngoscope investigative otolaryngology·2022

Same author

Long-term Anticoagulation Prevents Progression of Stages I and II Primary Osteonecrosis of the Hip in Patients With Familial Thrombophilia.

Orthopedics·2020

Same author

Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.

Cancer·2019

Search research articles

Related Experiment Video

Updated: May 12, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Testosterone, thrombophilia, and thrombosis.

Charles J Glueck¹, Caitlin Richardson-Royer, Reiker Schultz

¹1The Jewish Hospital Cholesterol Center, Cincinnati, OH, USA.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

|April 26, 2013

Summary

Testosterone therapy can lead to dangerous blood clots like deep venous thrombosis (DVT) and pulmonary embolism (PE), and bone death (osteonecrosis). Patients with undiagnosed clotting disorders (thrombophilia) are at higher risk.

Keywords:

anticoagulants blood coagulation factors clinical thrombophilia deep venous thrombosis endocrinology hypercoagulability testosterone

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Experiment Videos

Last Updated: May 12, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Area of Science:

Endocrinology
Hematology
Vascular Medicine

Background:

Testosterone therapy is increasingly used for various conditions.
The potential risks, especially thrombotic events, require careful consideration.
Undiagnosed thrombophilia-hypofibrinolysis may predispose individuals to adverse events.

Observation:

A study observed thrombosis, deep venous thrombosis (DVT), pulmonary embolism (PE), and hip-knee osteonecrosis in 14 patients after testosterone therapy.
These patients were previously healthy and had no prior history of thrombosis.
Several patients presented with previously undiagnosed thrombophilia-hypofibrinolysis, including Factor V Leiden, high Factor VIII, and PAI-1 4G4G homozygosity.

Findings:

Testosterone therapy was associated with the development of DVT, PE, and osteonecrosis in patients with underlying thrombophilia.
Recurrent DVT-PE occurred in some patients even with therapeutic anticoagulation when testosterone was continued.
High estradiol levels (a metabolite of testosterone) were observed in a significant percentage of men on testosterone therapy, suggesting a potential mechanism for E2-induced thrombophilia.

Implications:

Thrombophilia should be screened for before initiating testosterone therapy to mitigate risks.
The aromatization of testosterone to estradiol may play a role in testosterone-induced thrombophilia.
Clinicians should be vigilant for thrombotic complications in patients undergoing testosterone replacement therapy, particularly those with risk factors.